Welcome to our dedicated page for Pmv Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech is hard. PMV Pharmaceuticals’ SEC filings weave together p53 science, cash-burn math, and milestone disclosures that span hundreds of pages. If you’ve ever asked, “How do I find PMV Pharmaceuticals’ quarterly earnings report 10-Q filing?” or needed “PMV Pharmaceuticals insider trading Form 4 transactions” before the market reacts, you know the challenge.
Stock Titan solves it. Our AI-powered summaries turn dense 10-Ks into clear takeaways—R&D spend, cash runway, and risk factors—so “PMV Pharmaceuticals annual report 10-K simplified” is more than a promise. Real-time EDGAR feeds push “PMV Pharmaceuticals Form 4 insider transactions real-time” to your dashboard within seconds, letting you monitor executive stock moves the moment they’re filed. Need context on a sudden press release? Click the linked 8-K; our engine delivers “PMV Pharmaceuticals 8-K material events explained” with plain-English highlights.
Every filing type is covered: 10-Q earnings reports for trial-funding updates, 8-K notices for dose-escalation data, Schedule 13G for institutional positions, and the proxy statement for “PMV Pharmaceuticals proxy statement executive compensation” details. Use cases include comparing quarter-over-quarter burn, tracking pipeline progress through clinical milestones, and spotting “PMV Pharmaceuticals executive stock transactions Form 4” that precede key readouts. Whether you search for “understanding PMV Pharmaceuticals SEC documents with AI” or “PMV Pharmaceuticals earnings report filing analysis,” Stock Titan delivers concise answers, real-time alerts, and downloadable originals—so you spend time analyzing opportunities, not hunting for documents.
PMV Pharmaceuticals (PMVP) filed its Q3 2025 10‑Q, reporting continued clinical investment and a wider loss as it advances rezatapopt. For the three months ended September 30, 2025, net loss was $21.1 million ($0.40 per share). Operating expenses were $22.5 million, driven by research and development of $18.2 million and general and administrative of $4.3 million. Interest income was $1.5 million.
For the nine months, net loss was $59.7 million, with $56.4 million used in operating cash flow. Cash, cash equivalents, and marketable securities totaled $129.3 million as of September 30, 2025. The company states it has adequate liquidity to operate for the next 12 months. Common shares outstanding were 52,993,238 at quarter‑end; 53,211,507 were outstanding as of November 12, 2025.
PMV reported interim Phase 2 data updates for the PYNNACLE trial of rezatapopt and plans to complete enrollment in the ovarian cohort by the first quarter of 2026, with an NDA submission targeted for the first quarter of 2027. The at‑the‑market program had $113.8 million of capacity remaining, with no sales during the quarter.
PMV Pharmaceuticals (PMVP) furnished an 8-K announcing financial results for the third quarter ended September 30, 2025. The company issued a press release on November 12, 2025, which is attached as Exhibit 99.1 and incorporated by reference.
The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act, limiting potential Section 18 liability and incorporation unless specifically referenced.
PMV Pharmaceuticals (PMVP) reported an insider transaction by its President and CEO (also a Director). On 10/27/2025, he exercised an employee stock option and acquired 220,643 shares of common stock at $1.37 per share.
Following the transaction, he beneficially owned 451,109 shares directly, plus indirect holdings of 165,307, 453,582, and 56,978 shares held by family trusts. The exercised option covered 220,643 shares and now has 0 remaining.
PMV Pharmaceuticals (PMVP) — Form 4 insider transaction: An affiliated holder reported a sale of 1,000,000 shares of Common Stock on 10/23/2025 at a price of $1.52 per share. Following the transaction, 4,975,291 shares were reported as beneficially owned indirectly.
According to the footnotes, the shares are held by OrbiMed Private Investments V, LP, with OrbiMed Capital GP V LLC as general partner and OrbiMed Advisors LLC as managing member. The filing notes that the reporting persons may be deemed to share voting and investment power through these relationships and include customary disclaimers of beneficial ownership beyond pecuniary interest. The reporting relationship is indicated as Director and 10% Owner.
Tang Capital group reports collective ownership of 4,720,357 shares of PMV Pharmaceuticals common stock, representing 8.9% of the outstanding class. The filing discloses that Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP and Tang Capital Partners International, LP share voting and dispositive power over these shares. The ownership figures are based on 52,990,864 shares outstanding as of August 6, 2025, per the issuer's quarterly report.
The statement clarifies that the reported securities were not acquired to change or influence control of PMV and lists office addresses and organizational domiciles for the reporting entities and individuals.
PMV Pharmaceuticals, Inc. (PMVP) filed a Form 144 notice reporting a proposed sale of 2,283,654 shares of Common Stock through broker Themis Trading LLC with an approximate aggregate market value of $3,653,846.40. The filing lists the number of shares outstanding as 52,990,864 and gives an approximate sale date of 09/10/2025 on NASDAQ.
The securities were acquired on 09/29/2020 in the issuer's Initial Public Offering with cash payment. The filer certifies there were no securities sold in the past three months by the person for whose account the securities will be sold and represents they are unaware of any material nonpublic information about the issuer.
PMV Pharmaceuticals, Inc. (PMVP) filed an 8-K reporting a material event: the company issued a press release and hosted an investor webinar on September 10, 2025 to present interim monotherapy data for rezatapopt from the PYNNACLE Phase 2 trial in multiple solid tumors with a TP53 Y220C mutation. The press release is attached as Exhibit 99.2 and is incorporated by reference into the filing.
The filing notes the public dissemination of clinical interim results and the webinar but does not include the data tables or numerical results within the 8-K text itself. No financial results, enrollment counts, regulatory actions, or next-step timelines are disclosed in the provided excerpt.
PMV Pharmaceuticals (PMVP) reports that Sio Capital Management, LLC beneficially owns 3,735,396 shares of common stock, equal to 7.19% of the class. The filing states Sio has shared voting and shared dispositive power over these shares and reports no sole voting or dispositive power, reflecting an adviser-managed position held for client funds.
The percentage is calculated using 51,952,680 shares outstanding as reported by the issuer. The filing notes Sio acts as investment adviser to affiliated funds that are the record owners and discloses that Sio GP, LLC and Michael Castor may be viewed as having influence, although any such beneficial ownership is expressly disclaimed. The statement also certifies the securities are held in the ordinary course of business and not to change or influence control.
FAQ
What is the current stock price of Pmv Pharmaceuticals (PMVP)?
What is the market cap of Pmv Pharmaceuticals (PMVP)?
